Stock Exchange Releases

2019

7/15/2019 Orion completes enrollment in the REFALS Phase 3 trial studying the effect of oral Levosimendan in patients with amyotrophic lateral sclerosis (ALS)

6/27/2019 Publishing of Orion Corporation's Half Year Report for January-June 2019 on 17 July 2019

6/19/2019 1,767 Orion Corporation A shares converted into B shares

6/11/2019 Change in Orion Corporation's holding of treasury shares

5/13/2019 Orion Corporation completed share acquisitions

5/13/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 13.05.2019

5/10/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 10.05.2019

5/9/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 09.05.2019

5/8/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 08.05.2019

5/7/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 07.05.2019

5/7/2019 CORRECTION: ORION CORPORATION: ACQUISITION OF OWN SHARES 06.05.2019

5/6/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 06.05.2019

5/3/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 03.05.2019

5/2/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 02.05.2019

4/25/2019 Decision by the Board of Directors to acquire own shares

4/25/2019 Orion Group Interim Report January-March 2019

4/16/2019 297,000 Orion Corporation A shares converted into B shares

3/26/2019 Orion Corporation: Organising meeting of the Board of Directors

3/26/2019 Orion Corporation: Decisions by the AGM on 26 March 2019

3/4/2019 Orion Group Financial Statement documents 2018 and Corporate Governance Statement published

3/1/2019 Orion Corporation: Transfer of 47,279 own B shares on 1 March 2019

2/6/2019 The Board of Directors of Orion Corporation decided on an incentive plan for key persons

2/6/2019 Notice to the Annual General Meeting of Orion Corporation

2/6/2019 Orion Group Financial Statement Release for 2018

1/9/2019 Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2019 AGM of Orion Corporation

10/30/2018 Composition of the Nomination Committee of Orion Corporation

10/24/2018 Orion Group Interim Report January-September 2018

10/24/2018 Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The primary endpoint was met

9/19/2018 Changes in responsibility areas of the Orion Group Executive Management Board

7/18/2018 Orion Group Half-Year Financial Report January-June 2018

7/18/2018 Orion Corporation's financial reporting and Annual General Meeting in 2019

4/24/2018 Orion Group Interim Report January-March 2018

4/21/2018 Orion to sell its Orion Diagnostica division - Due to the transaction Orion updates its outlook

3/20/2018 Orion Corporation: Organising meeting of the Board of Directors

3/20/2018 Orion Corporation: Decisions by the AGM on 20 March 2018

3/1/2018 Orion Corporation: Transfer of 112,961 own B shares on 1 March 2018

2/26/2018 Orion Group Financial Statement documents 2017 and Corporate Governance Statement published

2/7/2018 Notice to the annual general meeting of Orion Corporation

2/7/2018 Orion Group Financial Statement Release for 2017

1/24/2018 Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2018 AGM of Orion Corporation

1/23/2018 Orion to investigate possible sale of Orion Diagnostica

10/26/2017 Composition of the Nomination Committee of Orion Corporation

10/26/2017 Orion Group Interim Report January-September 2017

8/1/2017 146,000 Orion Corporation A shares converted into B shares

7/19/2017 Orion Group Half-Year Financial Report January-June 2017

7/19/2017 Orion Corporation's financial reporting and Annual General Meeting in 2018

6/19/2017 187,133 Orion Corporation A shares converted into B shares

6/1/2017 248,549 Orion Corporation A shares converted into B shares

4/26/2017 Orion Group Interim Report January-March 2017

4/19/2017 398,245 Orion Corporation A shares converted into B shares

4/12/2017 Publishing of Orion Corporation's Interim Report for January-March 2017 on 26 April 2017

4/6/2017 Amendment to Sections 5 and 9(1) of the Articles of Association of Orion Corporation entered in the Trade Register

3/22/2017 Orion Corporation: Organising meeting of the Board of Directors

3/22/2017 Orion Corporation: Decisions by the AGM on 22 March 2017

3/1/2017 Orion Corporation: Transfer of 107,965 own B-shares on 1 March 2017

2/27/2017 Orion Group Financial Statement documents 2016 and Corporate Governance Statement published

2/13/2017 Change in Orion Group Executive Management Board as of 21 February 2017

2/8/2017 Notice to the annual general meeting of Orion Corporation

2/8/2017 Orion Group Financial Statement Release for 2016

1/27/2017 193,881 Orion Corporation A shares converted into B shares

1/25/2017 Publishing of Orion Corporation's Financial Statement Release for 2016 on 8 February 2017

1/24/2017 Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2017 AGM of Orion Corporation

12/22/2016 87,000 Orion Corporation A shares converted into B shares

11/18/2016 100,000 Orion Corporation A shares converted into B shares

10/25/2016 Orion Group Interim Report January-September 2016

10/11/2016 Publishing of Orion Corporation's Interim Report for January-September 2016 on 25 October 2016

10/5/2016 100,000 Orion Corporation A shares converted into B shares

9/7/2016 Composition of the Nomination Committee of Orion Corporation

7/19/2016 Orion Group Half-Yearly Report January-June 2016

7/19/2016 Orion Corporation's publication schedules for financial reporting in 2017

7/14/2016 100,000 Orion Corporation A shares converted into B shares

7/5/2016 Publishing of Orion Corporation's Half-Yearly Report for January-June 2016 on 19 July 2016

6/15/2016 Orion Corporation completed share acquisitions

6/15/2016 Orion Corporation: Acquisition of own shares 15 June 2016

6/15/2016 Orion upgrades full-year outlook for 2016

6/14/2016 Orion Corporation: Acquisition of own shares 14 June 2016

6/13/2016 Orion Corporation: Acquisition of own shares 13 June 2016

6/10/2016 Orion Corporation: Acquisition of own shares 10 June 2016

6/9/2016 Orion Corporation: Acquisition of own shares 9 June 2016

6/8/2016 Orion Corporation: Acquisition of own shares 8 June 2016

6/7/2016 Orion Corporation: Acquisition of own shares 7 June 2016

6/6/2016 Orion Corporation: Acquisition of own shares 6 June 2016

6/3/2016 Orion Corporation: Acquisition of own shares 3 June 2016

6/3/2016 Orion and Bayer expand clinical development program for ODM-201 (BAY-1841788) and initiate a new phase III study ARASENS in patients with metastatic hormone-sensitive prostate cancer

5/13/2016 100,000 Orion Corporation A shares converted into B shares

4/27/2016 Decision by the Board of Directors to acquire own shares

4/27/2016 Orion Group Interim Report January-March 2016

4/13/2016 Publishing of Orion Corporation's Interim Report for January-March 2016 on 27 April 2016

4/12/2016 125,000 Orion Corporation A shares converted into B shares

3/22/2016 Orion Corporation: Organising meeting of the Board of Directors

3/22/2016 Orion Corporation: Decisions by the AGM on 22 March 2016

3/1/2016 Orion Corporation: Transfer of 144,350 own B-shares on 1 March 2016

2/29/2016 Orion Group Financial Statement documents 2015 and Corporate Governance Statement published

2/2/2016 The Board of Directors of Orion Corporation decided on an incentive plan for key persons

2/2/2016 Notice to the Annual General Meeting of Orion Corporation

2/2/2016 Orion Group Financial Statement Release for 2015

1/27/2016 Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2016 AGM of Orion Corporation

1/19/2016 Publishing of Orion Corporation's Financial Statement Release for 2015 on 2 February 2016

12/9/2015 135,000 Orion Corporation A shares converted into B shares

10/29/2015 Composition of the Nomination Committee of Orion Corporation

10/27/2015 Orion Group Interim Report January-September 2015

10/13/2015 Publishing of Orion Corporation's Interim Report for January-September 2015 on 27 October 2015

10/8/2015 150,000 Orion Corporation A shares converted into B shares

9/24/2015 234,620 Orion Corporation A shares converted into B shares

8/13/2015 200,000 Orion Corporation A shares converted into B shares

7/28/2015 Orion Group Interim Report January-June 2015

7/28/2015 Orion Corporation's publication schedules for financial reporting in 2016

7/14/2015 Publishing of Orion Corporation's Interim Report for January-June 2015 on 28 July 2015

7/9/2015 Orion upgrades full-year outlook for 2015

6/15/2015 229,000 Orion Corporation A shares converted into B shares

5/18/2015 357,560 Orion Corporation A shares converted into B shares

4/29/2015 Orion Group Interim Report January-March 2015

4/27/2015 200,647 Orion Corporation A shares converted into B shares

4/24/2015 Orion upgrades full-year outlook for 2015

4/16/2015 Publishing of Orion Corporation's Interim Report for January-March 2015 on 29 April 2015

3/24/2015 Orion Corporation: Organising meeting of the Board of Directors

3/24/2015 Orion Corporation: Decisions by the AGM on 24 March 2015

3/2/2015 Orion Corporation: Transfer of 141,949 own B-shares on 2 March 2015

3/2/2015 Orion Group Financial Statement documents 2014 and Corporate Governance Statement published

2/4/2015 Notice to the Annual General Meeting of Orion Corporation

2/4/2015 Orion Group Financial Statement Release for 2014

1/27/2015 Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2015 AGM of Orion Corporation

1/23/2015 Publishing of Orion Corporation's Financial Statement Release for 2014 on 4 February 2015

12/16/2014 200,000 Orion Corporation A shares converted into B shares

11/21/2014 6,335 Orion A shares converted into B shares

10/22/2014 Composition of the Nomination Committee of Orion Corporation

10/21/2014 Orion Group Interim Report January-September 2014

10/15/2014 180,000 Orion A shares converted into B shares

10/8/2014 Publishing of Orion Corporation's Interim Report for January-September 2014 on 21 October 2014

10/3/2014 163,500 Orion A shares converted into B shares

9/24/2014 Disclosure Under Chapter 9 Section 10

9/22/2014 Orion announces amended settlement agreement over the proprietary drug Precedex®

9/15/2014 100,000 Orion A shares converted into B shares

9/4/2014 310,000 Orion A-shares converted into B-shares

7/29/2014 Orion Group Interim Report January-June 2014

7/29/2014 Orion Corporation's publication schedules for financial reporting in 2015

7/16/2014 Publishing of Orion Corporation's Interim Report for January-June 2014 on 29 July 2014

7/4/2014 150,000 Orion A-shares converted into B-shares

6/13/2014 200,000 Orion A-shares converted into B-shares

6/2/2014 Orion and Bayer enter global agreement for development and commercialization of novel prostate cancer treatment - Orion upgrades full-year outlook for 2014

4/29/2014 Orion Group Interim Report January-March 2014

4/22/2014 Publishing of Orion Corporation's Interim Report for January-March 2014 on 29 April 2014

4/15/2014 300,000 Orion A-shares converted into B-shares

4/14/2014 Orion receives first marketing authorisations for Bufomix Easyhaler® product

4/9/2014 Amendment of Section 12 of Articles of Association of Orion Corporation entered in the Trade Register

3/25/2014 Orion Corporation: Organising meeting of the Board of Directors

3/25/2014 Orion Corporation: Decisions by the AGM on 25 March 2014

3/3/2014 Orion Oyj : Transfer of 119,326 own B-shares on 3 March 2014

3/3/2014 Orion Group Financial Statement documents 2013 and Corporate Governance Statement published

2/4/2014 Notice to the Annual General Meeting of Orion Corporation

2/4/2014 Orion Group Financial Statement Release for 2013

1/30/2014 Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2014 AGM of Orion Corporation

1/22/2014 Publishing of Orion Corporation's Financial Statement Release for 2013 on 4 February 2014

12/19/2013 Orion Corporation signs license agreement with Janssen Pharmaceuticals, Inc. for the development and commercialization of its novel treatment for Alzheimer's disease

12/11/2013 Orion Corporation completed share acquisitions

12/11/2013 Orion Corporation: SHARE REPURCHASE December 11, 2013

12/10/2013 Orion Corporation: SHARE REPURCHASE December 10, 2013

12/9/2013 Orion Oyj: SHARE REPURCHASE December 9, 2013

12/5/2013 Orion Corporation: SHARE REPURCHASE December 5, 2013

12/5/2013 Orion settles patent dispute over the proprietary drug Precedex®

12/4/2013 Orion Corporation: SHARE REPURCHASE December 4, 2013

12/3/2013 Orion Corporation: SHARE REPURCHASE December 3, 2013

12/2/2013 Orion Corporation: SHARE REPURCHASE December 2, 2013

11/29/2013 Orion Corporation: SHARE REPURCHASE November 29, 2013

11/28/2013 Orion Corporation: SHARE REPURCHASE November 28, 2013

11/27/2013 Orion Corporation: SHARE REPURCHASE November 27, 2013

11/26/2013 Orion Corporation: SHARE REPURCHASE November 26, 2013

11/25/2013 Orion Corporation: SHARE REPURCHASE November 25, 2013

11/22/2013 Orion Corporation: SHARE REPURCHASE November 22, 2013

11/19/2013 Change in the responsibility areas of Orion Group Executive Management Board as of 1 January 2014

10/25/2013 150,000 Orion A-shares converted into B-shares

10/22/2013 Composition of the Nomination Committee of Orion Corporation

10/22/2013 Orion Group Interim Report January-September 2013

10/21/2013 Orion and Hospira have signed a license agreement to continue the collaboration with Precedex®

10/8/2013 Publishing of Orion Corporation's Interim Report for January-September 2013 on 22 October 2013

8/15/2013 100,000 Orion A-shares converted into B-shares

7/30/2013 Orion Group Interim Report January-June 2013

7/30/2013 Orion Corporation's publication schedules for financial reporting in 2014

7/25/2013 Orion and Mylan settle patent dispute over the proprietary drug Stalevo®

7/16/2013 Publishing of Orion Corporation's Interim Report for January-June 2013 on 30 July 2013

6/19/2013 37,502 Orion A-shares converted into B-shares

6/11/2013 Listing prospectus for Orion Corporation's EUR 150 million bond available

6/4/2013 Orion Corporation issues a EUR 150 million domestic bond on 11 June 2013

6/3/2013 Orion Diagnostica's statutory co-operation negotiations completed

5/20/2013 Orion Corporation is preparing to issue a bond

5/20/2013 225,000 Orion A-shares converted into B-shares

4/23/2013 Decision by the Board of Directors to acquire own shares

4/23/2013 Orion Group Interim Report January-March 2013

4/19/2013 700,000 Orion A-shares converted into B-shares

4/10/2013 Orion Diagnostica proposes co-operation negotiations on streamlining its operations and reducing no more than 80 employees in Finland

4/9/2013 Orion invites analysts and media to Q1 conference on Tuesday 23 April 2013

3/21/2013 Orion has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the Easyhaler® product family

3/19/2013 Orion Corporation: Organising meeting of the Board of Directors

3/19/2013 Orion Corporation: Decisions by the AGM on 19 March 2013

3/1/2013 Transfer of 137,000 own B-shares on 1 March 2013

2/26/2013 Orion Group Annual Report 2012 and Corporate Governance Statement published

2/5/2013 The Board of Directors of Orion Corporation decided on an incentive plan for key persons

2/5/2013 Notice to the Annual General Meeting of Orion Corporation

2/5/2013 Orion Group Financial Statement Release for 2012

1/22/2013 Orion invites analysts and media to Financial Statement Release conference on Tuesday 5 February 2013

1/21/2013 Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2013 AGM of Orion Corporation

1/21/2013 Annual Summary of Stock Exchange Releases published in 2012

1/16/2013 31,900 Orion A-shares converted into B-shares

12/20/2012 Orion and Mylan settle patent dispute over the proprietary drug Comtan®

12/20/2012 203,000 Orion A-shares converted into B-shares

11/30/2012 Orion is planning to apply for a marketing authorisation for combined budesonide-formoterol formulation of the Easyhaler® product family

11/19/2012 823,000 Orion A-shares converted into B-shares

10/23/2012 Composition of the Nomination Committee of Orion Corporation

10/23/2012 Orion Group Interim Report January-September 2012

10/9/2012 Orion upgrades full-year outlook for 2012

10/9/2012 Orion invites analysts and media to Q3 news conference on Tuesday 23 October 2012

9/12/2012 200,000 Orion A-shares converted into B-shares

9/5/2012 Orion Corporation: Correction to the English version of the stock exchange release

9/5/2012 Disclosure Under Chapter 2 Section 10

7/31/2012 Orion Group Interim Report January-June 2012

7/31/2012 Orion Corporation's publication schedules for financial reporting in 2013

7/16/2012 Orion invites analysts and media to Q2 news conference on Tuesday 31 July 2012

7/5/2012 200,000 Orion A-shares converted into B-shares

7/3/2012 Orion upgrades full-year outlook for 2012

5/1/2012 U.S. District Court gives decision on Precedex® patent litigation

4/26/2012 Orion sues Mylan in the U.S. to enforce its U.S. patents covering the proprietary drug Stalevo®

4/24/2012 Orion Group Interim Report January-March 2012

4/10/2012 Orion invites analysts and media to Q1 news conference on Tuesday 24 April 2012

4/10/2012 Orion Corporation: 300,000 Orion A-shares converted into B-shares

3/26/2012 Orion comments on ANDA filed by Mylan Pharmaceuticals Inc. for a generic version of Orion's proprietary drug Stalevo® in the United States

3/20/2012 Orion Oyj : Orion Corporation: Organising meeting of the Board of Directors

3/20/2012 Orion Oyj : Decisions by the AGM on 20 March 2012

3/12/2012 Orion Corporation: Transfer of 87,763 own B-shares on 12 March 2012

3/6/2012 Orion Group Annual Report 2011 published

2/7/2012 Notice to the Annual General Meeting of Orion Corporation

2/7/2012 Orion Group Financial Statement Release for 2011

2/7/2012 Orion continues development of inhalable budesonide-formoterol combined formulation

1/30/2012 Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2012 AGM of Orion Corporation

1/20/2012 Orion Corporation: Annual Summary of Stock Exchange Releases published in 2011

1/20/2012 Orion invites analysts and media to Financial Statement Release conference on Tuesday 7 February 2012

12/20/2011 Orion Corporation: 201,000 Orion A-shares converted into B-shares

11/7/2011 Disclosure Under Chapter 2 Section 10

11/7/2011 53,428 Orion A-shares converted into B-shares

10/25/2011 Change in Orion Group Executive Management Board as of 1 January 2012

10/25/2011 Orion Group Interim Report January-September 2011

10/11/2011 Orion invites analysts and media to Q3 news conference on Tuesday 25 October 2011

9/26/2011 Disclosure Under Chapter 2 Section 10

9/23/2011 400,000 Orion A-shares converted into B-shares

9/21/2011 Composition of the Nomination Committee of Orion Corporation

9/21/2011 Orion receives European marketing authorisation for dexdor®

9/14/2011 400,000 Orion A-shares converted into B-shares

8/19/2011 136,231 Orion A-shares converted into B-shares

8/2/2011 Orion Group Interim Report January-June 2011

8/2/2011 Orion Corporation's publication schedules for financial reporting in 2012

7/22/2011 Orion receives positive CHMP opinion for new intensive care sedative, dexdor® (dexmedetomidine)

7/18/2011 Orion invites analysts and media to Q2 news conference on Tuesday 2 August 2011

6/22/2011 100,000 Orion A-shares converted into B-shares

6/9/2011 628,914 Orion A-shares converted into B-shares

5/5/2011 173,500 Orion A-shares converted into B-shares

4/27/2011 Orion Group Interim Report January-March 2011

4/20/2011 397,408 Orion A-shares converted into B-shares

4/18/2011 Orion invites analysts and media to Q1 news conference on Wednesday 27 April 2011

4/13/2011 Orion upgrades full-year outlook for 2011

3/31/2011 Orion Corporation: Organising meeting of the Board of Directors

3/31/2011 Orion Corporation: Decisions by the AGM on 31 March 2011

3/31/2011 President and CEO Timo Lappalainen today at Annual General Meeting of Orion Corporation: Orion's sales developed well in early 2011

3/9/2011 Orion Group Annual Report 2010 published

3/1/2011 Orion Corporation: Transfer of 102,900 own B-shares

2/9/2011 Notice to the Annual General Meeting of Orion Corporation

2/9/2011 Orion Group Financial Statement Release for 2010

1/31/2011 Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2011 AGM of Orion Corporation

1/24/2011 Orion sues Mylan in the U.S. to enforce its U.S. patent covering the proprietary drug Comtan®

1/20/2011 Orion invites analysts and media to Financial Statement Release conference on Wednesday 9 February 2011

1/19/2011 Annual Summary of Stock Exchange Releases published in 2010

1/14/2011 79,866 Orion A-shares converted into B-shares

12/15/2010 Orion comments on ANDA filed by Mylan Pharmaceuticals Inc. for a generic version of Orion's proprietary drug Comtan® (entacapone) in the United States

11/12/2010 321,946 Orion A-shares converted into B-shares

11/1/2010 Composition of the Nomination Committee of Orion Corporation

10/26/2010 Orion Group Interim Report January-September 2010

10/20/2010 European Medicines Agency has initiated the review of Orion´s dexmedetomidine marketing authorisation application

10/15/2010 Disclosure Under Chapter 2 Section 9

10/11/2010 Orion invites analysts and media to Q3 news conference on Tuesday 26 October 2010

9/24/2010 Change in Orion Group Executive Management Board as of 1 Jan 2011

9/1/2010 Orion: Change in the holding of own shares

8/20/2010 Orion comments on today's FDA release on safety review of Stalevo®

8/13/2010 435,019 Orion A-shares converted into B-shares

8/10/2010 Orion Group Interim Report January-June 2010

8/10/2010 Orion Corporation's publication schedules for financial reporting in 2011

7/19/2010 Orion invites analysts and media to Q2 news conference on Tuesday 10 August 2010

6/22/2010 Orion and Sun settle patent dispute

6/17/2010 20,138 Orion A-shares converted into B-shares

6/15/2010 Composition of R&D Committee as of 15 June 2010

6/14/2010 Orion upgrades full-year outlook for 2010

6/1/2010 1,100,000 Orion A-shares converted into B-shares

5/18/2010 Decision by the Board of Directors to repurchase own shares

5/18/2010 Change in Orion Group Executive Management Board as of 1 Oct 2010

4/30/2010 1,700,000 Orion A-shares converted into B-shares

4/27/2010 Orion Group Interim Report January-March 2010

4/20/2010 Dexmedetomidine Phase III program completed with positive results

4/15/2010 Orion invites analysts and media to Q1 news conference on Tuesday 27 April 2010

4/8/2010 Amendment of Section 12 of Articles of Association entered in the Trade Register

4/1/2010 Orion comments on FDA release on Stalevo

3/24/2010 Orion Corporation: Matti Kavetvuo Vice Chairman of the Board of Directors. Compositions of Board committees

3/24/2010 Orion Corporation: Decisions by the AGM on 24 March 2010

3/11/2010 Orion Corporation: Member of the Board of Directors of Orion Corporation Leena Palotie passed away

3/2/2010 Orion Group Annual Report 2009 published

3/1/2010 Orion Corporation: Transfer of 65,606 own B-shares on 1 March 2010

2/18/2010 The Board of Directors of Orion Corporation decided on an incentive plan for key persons

2/9/2010 Notice to the Annual General Meeting of Orion Corporation

2/9/2010 Orion Group Financial Statement Release of 2009

2/1/2010 Orion invites analysts and media to Financial Statement Release conference on 9 February 2010

1/20/2010 Annual Summary of Stock Exchange Releases published in 2009

1/19/2010 ORION CORPORATION: Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2010 AGM of Orion Corporation, 19 Jan 2010

1/4/2010 200,000 Orion A-shares converted into B-shares

12/4/2009 Orion clarifies information emanating from Capital Markets Day

11/27/2009 100,000 Orion A-shares converted into B-shares

10/26/2009 Orion Group Interim Report January-September 2009

10/26/2009 Orion Corporation's publication schedules for financial reporting in 2010

10/21/2009 Orion withdraws US application for extending the indication of Stalevo®

10/6/2009 Orion invites analysts and media to Q3 news conference on Monday 26 October 2009

9/21/2009 Composition of the Nomination Committee of Orion Corporation

9/4/2009 Orion and Hospira,Inc. sue Sandoz companies in the U.S. to enforce their U.S. Patents covering the proprietary drug Precedex®

8/7/2009 Orion: Correction to English version of Interim Report 1-6/2009

8/7/2009 Orion Group Interim Report January-June 2009

7/31/2009 Orion comments on ANDA filed by Sandoz Inc. for a generic version of Orion's proprietary drug Precedex® (dexmedetomidine hydrochloride 100 mcg base/ml ) in the United States

6/10/2009 Orion invites analysts and media to Q2 news conference on Friday 7 August 2009

5/6/2009 Orion reacquires rights for i.v. levosimendan (Simdax®)

4/29/2009 Orion and Wockhardt settle patent dispute

4/27/2009 Orion Group Interim Report 1-3/2009

4/20/2009 Orion invites to a Q1 news conference on Monday 27 April 2009

4/14/2009 Amendments to Orion's Articles of Association entered in the Trade Register

3/23/2009 Orion Corporation: Jukka Ylppö Vice Chairman of the Board of Directors. Compositions of Board committees

3/23/2009 Orion Corporation: Decisions by the AGM on 23 March 2009

3/6/2009 Orion withdraws EU application for extending the indication of Stalevo®

3/5/2009 Orion Corporation: Transfer of 44,806 own B-shares

3/4/2009 Orion Group Annual Report 2008 published

2/24/2009 Orion: Primary objective of STRIDE-PD study was not achieved

2/6/2009 Matters to be handled at the AGM of Orion Corporation on 23 March 2009

2/6/2009 Orion Group Financial Review of 2008

1/28/2009 Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2009 AGM of Orion Corporation

1/16/2009 Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2008

1/15/2009 Orion sues Wockhardt USA LLC and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo®

1/7/2009 Orion's statutory negotiations completed. Personnel to be reduced by about 205 in Finland

12/11/2008 Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® (25/200/100; 37.5/200/150 and 50/200/200 mg strengths) in the United States

12/8/2008 Orion sues Wockhardt USA, Inc. and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo®

11/19/2008 Orion to renew operational model of pharmaceutical R&D. Negotiation proposal on reduction of up to 300 employees in Finland

11/12/2008 Orion sues Sun Pharma Global, Inc. in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Comtan®

11/3/2008 Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® in the United States

10/29/2008 Composition of the Nomination Committee of Orion Corporation

10/28/2008 Orion Corporation's publication schedules for financial reporting in 2009

10/28/2008 Orion Group Interim Report 1-9/2008

10/7/2008 Orion comments on new ANDA by Sun Pharma Global, Inc. for generic entacapone (Orion's proprietary drug Comtan®) in the United States

9/12/2008 Orion updates progress with dexmedetomidine trials

8/5/2008 Orion Group Interim Report 1-6/2008

7/23/2008 Orion Corporation publishes Interim Report Q2/2008 on 5 August 2008

5/9/2008 Orion has decided not to continue the development of a new COMT inhibitor candidate

4/25/2008 Orion Group Interim Report 1-3/2008

4/15/2008 Orion seeking broader indication for Stalevo

3/25/2008 Orion Corporation: Jukka Ylppö Vice Chairman of the Board of Directors. Compositions of Board committees

3/25/2008 Orion Corporation: Decisions by the AGM on 25 March 2008

2/28/2008 Orion Group Annual Report 2007 published

2/25/2008 ORION OYJ: GTx ANNOUNCED PHASE III CLINICAL DATA FOR TOREMIFENE CITRATE 80 mg

2/7/2008 Orion sues Sun Pharmaceuticals in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Stalevo®

2/7/2008 Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2007

2/7/2008 Matters to be handled at Orion's AGM on 25 March 2008

2/7/2008 Orion Group Financial Review of 2007

1/30/2008 Recommendation by the Nomination Committee concerning Board of Directors to be elected by the AGM of Orion Corporation

1/24/2008 Positive primary endpoint from FIRST-STEP study with Stalevo in early Parkinson's Disease

1/2/2008 Orion comments on new challenge by Sun Pharmaceutical Industries Ltd., India, of Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Stalevo® in the United States

11/27/2007 Announcement by Orion Corporation in accordance with section 10 of chapter 2 of the Finnish Securities Market Act

11/15/2007 Appointments into Orion's Executive Management Board as of 1 January 2008

11/13/2007 Orion sues Sun Pharmaceuticals in the U.S. to enforce a patent for Stalevo®

10/24/2007 Composition of the Nomination Committee of Orion Corporation

10/24/2007 Orion Corporation's publication schedules for financial reporting in 2008

10/24/2007 Orion Group Interim Report 1-9/2007

10/1/2007 Orion comments on ANDA filing of generic versions of Orion's proprietary drug Stalevo® in the United States

9/13/2007 Orion sues generic drug companies in the U.S. to enforce patents for entacapone (Orion's proprietary drug Comtan®)

9/11/2007 New President and CEO for Orion Corporation as of 1 January 2008

8/13/2007 Orion comments on ANDA filing of generic entacapone (Orion's proprietary drug Comtan®) in the United States

8/6/2007 Decision of the Board of Directors of Orion on repurchasing own shares

8/6/2007 Orion Group Interim Report 1-6/2007

4/25/2007 Orion Group Interim Report 1-3/2007

4/25/2007 Orion's partner discontinues development of levosimendan (Simdax) in the US

4/2/2007 Jukka Ylppö Vice Chairman of the Board of Directors of Orion Corporation. Compositions of Board committees

4/2/2007 Decisions by the AGM of Orion Corporation on 2 April 2007

3/8/2007 Amendment to the Annual Report 2006 of Orion Corporation concerning holdings of Board members

3/1/2007 Orion Group Annual Report 2006 published

2/6/2007 Matters to be handled at Orion's AGM on 2 April 2007

2/6/2007 Orion updates progress with Simdax (i.v. levosimendan):

2/6/2007 Orion Group Financial Review (proforma) 1-12/2006

2/6/2007 Bulletin of Orion Corporation Financial Statements for 1 July - 31 December 2006

1/29/2007 Recommendation by the Nomination Committee concerning Board of Directors to be elected by the AGM of Orion Corporation

1/24/2007 Share-based incentive plan for ca. 30 key persons in Orion

1/24/2007 Change in the Executive Management Board of the Orion Group as of 1 February 2007

11/2/2006 Publication schedule for Orion's financial reporting in 2007

11/2/2006 Orion Group Interim Report 7-9/2006 and Financial Review (proforma) 1-9/2006

10/20/2006 Reijo Salonen appointed to Orion's new Senior Vice President, Research and Development

10/16/2006 Composition of the Nomination Committee of Orion Corporation

10/16/2006 Decisions by the shareholders' meeting of the demerged Orion

10/9/2006 Changes in the Executive Management Board of the Orion Group as of 1 November 2006

9/14/2006 Final account of the demerged Orion Corporation

8/31/2006 Change in Orion's R&D management

8/7/2006 Orion to publish its Interim Report for 7-9/2006 already on 2 November 2006

8/7/2006 Orion Group Financial Review 1-6/2006

7/13/2006 Determination of acquisition costs of Orion Corp. and Oriola-KD Corp. shares for Finnish taxation